Immunodeficiency Syndrome

The FDA granted priority review to a new drug application for leniolisib to treat activated phosphoinositide 3-kinase delta syndrome in adults and adolescents aged 12 years and older, according to a Pharming Group press release.

Most children with a primary immunodeficiency experienced fatigue, which can be evaluated via a review of these patients’ charts and use of a generic questionnaire, according to a study published in Journal of Clinical Immunology.

Researchers reported high patient satisfaction with cardio-oncology telehealth consultations during the COVID-19 pandemic.